Prof Dennis Slamon speaks to ecancer at ESMO 2019 in Barcelona about the MONALEESA-3 study looking at the use of the CDK4/6 inhibitor ribociclib plus fulvestrant in postmenopausal patients with HR positive and HER2 negative advanced breast cancer.
He reports that there is a significant improvement in overall survival in patients who are receiving the combination of ribociclib plus fulvestrant.
Prof Slamon says that the trial supports the potential of CDK4/6 inhibitors in the first-line setting.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
